A phase II open-label study evaluating hemostatic activity, pharmacokinetics and safety of recombinant porcine factor VIII (OBI-1) in hemophilia A patients with alloantibody inhibitors directed against human FVIII

被引：14

作者：

Mahlangu, Johnny ^{[1
]}

Andreeva, Tatiana A. ^{[2
]}

Macfarlane, Donald ^{[3
]}

Reding, Mark T. ^{[4
]}

Walsh, Christopher ^{[5
]}

Ritchie, Bruce ^{[6
]}

Ewing, Nadia ^{[7
]}

Kessler, Craig M. ^{[8
]}

Kempton, Christine ^{[9
]}

Libby, Edward ^{[10
]}

Zozulya, Nadezda ^{[11
]}

Shapiro, Amy D. ^{[12
]}

St-Louis, Jean ^{[13
]}

Warrier, Indira ^{[14
]}

Hoots, W. Keith ^{[15
]}

Gruppo, Ralph A. ^{[16
]}

Mueksch, Josef N. ^{[17
]}

机构：

[1] Johannesburg Hosp, Parktown, South Africa

[2] St Petersburg State Med Inst, St Petersburg, Russia

[3] Univ Iowa Hosp & Clin, Iowa City, IA 52242 USA

[4] Univ Minnesota Hosp, Minneapolis, MN USA

[5] Mt Sinai Sch Med, New York, NY USA

[6] Univ Alberta, Edmonton, AB, Canada

[7] City Hope Natl Med Ctr, Duarte, CA USA

[8] Georgetown Univ, Med Ctr, Washington, DC USA

[9] Emory Childrens Ctr, Atlanta, GA USA

[10] Univ New Mexico, Albuquerque, NM 87131 USA

[11] Russian Acad Med Sci, Hematol Res Ctr, Moscow, Russia

[12] Indiana Univ, Hemophilia & Thrombosis Ctr Indiana, Indianapolis, IN USA

[13] Hop Maison Neuve Rosemont, Montreal, PQ, Canada

[14] Childrens Hosp Michigan, Detroit, MI 48201 USA

[15] Gulf States Hemophilia & Thrombophelia Ctr, Houston, TX USA

[16] Cincinnati Childrens Hosp, Cincinnati, OH USA

[17] Octagen Corp, Blue Bell, PA USA

来源：

BLOOD | 2007年 / 110卷 / 11期

关键词：

D O I：

10.1182/blood.V110.11.783.783

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

783

引用

页码：241A / 241A

页数：1

共 50 条

[31] The safety, tolerability, and pharmacokinetics of BAT8001 in patients with human epidermal growth factor receptor-2 (HER2)-positive metastatic breast cancer: An open-label, dose-up, phase 1 study
Wang, Shusen
Hong, Ruoxi
Wang, Liye
Xu, Fei
Xia, Wen
CANCER RESEARCH, 2020, 80 (04)
[32] Phase 1b open-label study evaluating the safety, pharmacokinetics, and preliminary efficacy of ABT-165 plus FOLFIRI in patients with second-line (2L) colorectal cancer (CRC)
Wainberg, Z.
Strickler, J.
Gordon, M.
Barve, M.
Wang, L.
Yue, H.
Motwani, M.
Kasichayanula, S.
Naumovski, L.
Hamilton, E.
ANNALS OF ONCOLOGY, 2018, 29 : 66 - 66
[33] A Phase 1/2a, multicenter, open-label, non-randomized first-in-human study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of DB-1303 in patients with advanced/metastatic solid tumors
Hamilton, Erika
Zhang, Jian
Liu, Liming
Gao, Jie
Shi, Rong
Liu, Shengxue
Wei, Gu
Qiu, Yang
Moore, Kathleen
CANCER RESEARCH, 2023, 83 (08)
[34] Achievement of Normal Circulating Factor VIII Activity Following Bmn 270 AAV5-FVIII Gene Transfer: Interim, Long-Term Efficacy and Safety Results from a Phase 1/2 Study in Patients with Severe Hemophilia a
Pasi, K. John
Rangarajan, Savita
Kim, Benjamin
Lester, Will
Perry, David
Madan, Bella
Tavakkoli, Fatemeh
Yang, Ke
Pierce, Glenn F.
Wong, Wing Yen
BLOOD, 2017, 130
[35] An open-label, multicenter phase 1 study to characterize safety, tolerability, preliminary antitumor activity, pharmacokinetics, and pharmacodynamics of VIP943 monotherapy in patients with advanced CD123+hematologic malignancies.
Strickland, Stephen Anthony
Curran, Emily K.
Jamy, Omer Hassan
Percival, Mary-Elizabeth
Johnson, Amy J.
Birkett, Joseph
Huang, Xin
Frigault, Melanie M.
Lerchen, Hans-Georg
Stelte-Ludwig, Beatrix
Navarro, Tasheda
Peck, Jim
Gross, Wyatt
Izumi, Raquel
Hamdy, Ahmed M.
Daver, Naval Guastad
JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
[36] A first-in-human, phase 1a/1b, open-label, dose-escalation and expansion study to investigate the safety, pharmacokinetics, and antitumor activity of the RAF dimer inhibitor BGB-3245 in patients with advanced or refractory tumors
Schram, Alison M.
Subbiah, Vivek
Sullivan, Ryan
Cosman, Rasha
Liu, Jia
Sbar, Eric I.
Thuy Hoang
Chen, Jiarong
Johnson, Mark
Amoruccio, Vincent
Shearer, Todd
Kamal, Adeela
Lewis, Jocelyn
Shao, Wenlin
Edris, Badreddin
Luo, Lusong
Desai, Jayesh
CANCER RESEARCH, 2023, 83 (08)
[37] A phase II open-label clinical study of efficacy and safety of recombinant human N-acetylgalactosamine 4-sulfatase (rhASB) enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux-Lamy syndrome).
Harmatz, P
Ketteridge, D
Steiner, R
Simon, J
Waterson, J
Oates, S
Giugliani, R
Schwartz, I
Guffon, N
Miranda, CS
Keppen, L
Teles, EL
Hopwood, J
AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 73 (05) : 623 - 623
[38] An open-label, MRCT phase I/II study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of first-in-class bi-ligand-drug conjugate CBP-1019 in patients (pts) with advanced solid tumors
Liu, D.
Shen, L.
Sun, Y.
Li, N.
Marathe, O.
Huang, R.
Shao, J.
Xu, M.
Pan, B.
Pan, F.
Gao, S.
Gong, J.
ANNALS OF ONCOLOGY, 2024, 35 : S512 - S513
[39] Trial in Progress: The Phase III, Randomized, Open-Label, Multicenter COMMODORE 1 Study Evaluating the Efficacy and Safety of Crovalimab Versus Eculizumab in Adult and Adolescent Patients with Paroxysmal Nocturnal Hemoglobinuria Currently Treated with Complement Inhibitors
Risitano, Antonio
Roth, Alexander
Kulasekararaj, Austin
Pu, Jeffrey
Nishimura, Jun-Ichi
Wright, Lilyan
Appius, Anita
Sostelly, Alexandre
Sreckovic, Sasha
Vignal, Charlotte
Munir, Talha
BLOOD, 2020, 136
[40] A phase Ib/II, open-label, multicenter study to evaluate the safety, efficacy, and pharmacokinetics/pharmacodynamics of avb3/5 integrin and neuropilin-1 targeting peptide LSTA1 in patients with metastatic pancreatic ductal adenocarcinoma
Xu, Jianming
Niu, Zuoxing
Bai, Yuxian
Qiu, Wensheng
Cui, Jiuwei
Qu, Xiujuan
Wu, Zheng
Zha, Yong
Zhang, Tao
Cheng, Wei
Han, Cuicui
Si, Meimei
Li, Lingyan
Kang, Xiaoyan
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)

← 1 2 3 4 5 →